Compliance
Customers don't need to clear documents through internal review or negotiate confidentiality before running an analysis.
For investment firms
Assess merger risk before the market does.
Taimet is purpose-built for merger antitrust risk. A full analysis in minutes built exclusively with public data and cited sources your team can check before the next call.
The edge is knowing the regulatory outcome before the risk is priced in. Taimet compresses the full antitrust read - markets, overlaps, vertical exposure, enforcement context, and political posture - into a scored prediction of what federal and state enforcers will do.
What will regulators actually do?
The core question is not "Is there regulatory risk?" It is "what will regulators actually do?" Early termination, second request, or remedies? The answer determines whether the spread compresses or widens. Manual research takes a day or more to approach that question. And you'll still call your go-to attorney for confirmation. General-purpose LLMs are faster, but confidently wrong on antitrust in ways experts can catch and non-experts cannot: wrong guidelines, fabricated citations, vague industry positions that sound right but are not.
Taimet is built to answer the outcome question directly: a full antitrust read in 10-25 minutes, scored against six real-world regulatory outcome bands - from early termination through remedies to adverse decision - with exclusively public data and cited sources.
Where the edge comes from
Expert-grade antitrust with public data - at market speed, with sources that hold up.
Map overlaps before the market prices them in
Taimet surfaces relevant product and geographic markets - including overlaps that are not obvious from headlines or initial coverage. You get the full picture, with cited sources, early enough to act on it.
A prediction of the real-world regulatory outcome
The Taimet Score™ maps to six real-world outcome bands - early termination, pull and refile, second request, remedies, trial on the merits, adverse decision - representing what federal and state enforcers are likely to do. These are not abstract risk levels; they are outcome predictions. A score in the 51-70 band means a second request is possible. 71-85 puts the deal in remedies territory. A full written report sits behind every score.
A second read - not confirmation, but refinement
You already have the right instinct. The value is in pressure-testing its edges. Taimet surfaces enforcement posture, state AG alignment, and less-visible vertical exposure that don't appear on a first pass. The score isn't there to validate - it's there to sharpen. And the delta is where conviction becomes precision.
Consistency across deals
Traditional analysis depends heavily on which lawyer or analyst you ask. Taimet standardizes the framework, so investors can compare deals apples-to-apples across sectors and time.
Cited sources you can verify before the next call
Every material claim traces to a public source. When Taimet's read departs from your thesis, the citation trail tells you exactly where to look. It confirms when you are right and surfaces exactly where your hypothesis needs reexamining.
Exclusively public data - your edge is legal by design
Taimet is built with public records, SEC filings, regulatory documents, and news - never party-supplied materials or confidential information. The analysis itself creates no insider exposure. Work fast on a live deal without that risk.
Six bands, calibrated to real-world outcomes
Every analysis produces a 0-100 Taimet Score™, mapped to six interpretive bands. The bands are designed to reflect the actual range of merger outcomes - from quick clearance through trial on the merits to adverse decision - as an experienced attorney would predict them.
Score Ranges
Low riskHigh risk
1–25Early termination
Parties may be granted early termination of the HSR waiting period when the transaction is unlikely to substantially lessen competition.
26–50Pull and refile
The merging parties can withdraw and refile to give enforcers more time, so review often extends beyond the usual 30-day window.
51–70Second request
These deals carry a higher risk of a second request and a longer review; toward the top of the band, negotiated outcomes become more common.
71–85Remedies
A complaint and structural or behavioral remedies are plausible, with lower scores leaning toward settlement and higher scores toward litigation.
86–95Trial on the merits
Substantial antitrust effects with few likely remedies can produce a litigated trial on the merits.
96–100Adverse decision
Strong anticompetitive concerns and limited remedies may lead to trial and an adverse decision against the merging parties.
1 to 25, Early termination: Parties may be granted early termination of the HSR waiting period when the transaction is unlikely to substantially lessen competition. 26 to 50, Pull and refile: The merging parties can withdraw and refile to give enforcers more time, so review often extends beyond the usual 30-day window. 51 to 70, Second request: These deals carry a higher risk of a second request and a longer review; toward the top of the band, negotiated outcomes become more common. 71 to 85, Remedies: A complaint and structural or behavioral remedies are plausible, with lower scores leaning toward settlement and higher scores toward litigation. 86 to 95, Trial on the merits: Substantial antitrust effects with few likely remedies can produce a litigated trial on the merits. 96 to 100, Adverse decision: Strong anticompetitive concerns and limited remedies may lead to trial and an adverse decision against the merging parties.
Built by an enforcer who spent twenty years inside the work
Taimet's Founder, Gwendolyn Lindsay Cooley, served nearly two decades as Wisconsin's Assistant Attorney General for Antitrust. She chaired the National Association of Attorneys General Multistate Antitrust Task Force, leading coalitions of state and federal enforcers and collaborating with international counterparts. She co-led the trial team for the States' challenge to T-Mobile/Sprint - one of the highest-profile telecom antitrust cases in recent history.
Most AI products are built by AI researchers who consult lawyers. Taimet was built by a lawyer who spent two decades doing this work, in partnership with an engineer with two decades building production software. The reasoning encoded into the system isn't theoretical. It's hers.
Read more about Gwendolyn's background →
Things only an enforcer would know
There is a small body of working knowledge - the kind held by people who have spent years doing this - that determines how mergers actually get analyzed. None of it is in a textbook. Almost none of it is in an LLM's training data. All of it is in Taimet.
Pharmaceutical market definition
Small-molecule drugs are in the same market only if they share an identical molecular structure and are AB-rated for each other. Biologics are in the same market only if they’re biosimilars and treat the same disease. The distinction determines whether a pharma deal looks like a horizontal overlap or a non-issue. Most analysts don’t know it. Taimet does - and applies it automatically.
State enforcement patterns
Different state attorneys general challenge different kinds of mergers. Some are aggressive on hospital consolidation. Others on agriculture. Others on tech. Taimet knows which jurisdictions are likely to act on which transactions, which state-level enforcement theories apply, and which mergers will draw multistate coalitions.
Where the evidence actually lives
Pricing-power evidence often surfaces in investor presentations. Foreclosure intent shows up in board materials. Public statements about competitive intent surface in regulatory filings before they show up in press releases. Taimet knows where to look - because the person who designed it spent two decades looking there.
These are three examples among dozens. The full set is what makes the difference between an analysis that sounds expert and one that actually is.
An analyst that doesn't have to specialize
Taimet identifies the transaction structure automatically - horizontal, vertical, conglomerate, cross-market, cluster market, private equity, or any combination. Most real deals involve more than one structure at once. A private equity roll-up in a health services market may face horizontal overlap, vertical foreclosure concerns, and cumulative competition effects simultaneously. The system applies the right analytical frameworks for each without the user needing to classify the deal first.
Horizontal
Companies with overlap in both product and geographic market, competing directly in the same space.
Vertical
Companies in a direct or indirect vertical relationship within the same supply chain.
Conglomerate
An acquisition in an unrelated industry, with no economic relationship between the companies.
Cluster market
Multiple products sold together as a bundle (e.g., supermarket goods, hospital services).
Cross-market
Companies selling identical products but operating in separate, non-overlapping geographic markets.
Private equity
A private equity firm acquiring a company in a market where it has no existing holdings.
Across every industry
The FTC specializes. The DOJ specializes. Taimet doesn't.
Both federal agencies build their enforcement staffs around industry teams. A human analyst has to choose what to know deeply. That structural constraint doesn't apply to Taimet. The same system that analyzes a pharmaceutical merger - where market definition turns on molecular structure and AB-rating - analyzes a semiconductor deal, a regional hospital consolidation, or a mining joint venture. No configuration required. For the first time, the analytical breadth of the entire merger landscape is available to a single analyst.
PharmaceuticalsSemiconductorsHealthcare & HospitalsBig TechMining & ResourcesFinancial ServicesAgricultureReal EstateManufacturingTelecommunicationsRetail & Consumer GoodsEnergy & UtilitiesMedia & EntertainmentDefense & AerospaceTransportation & LogisticsFood & BeverageInsuranceBiotechnology
A screening tool, not a substitute for judgment
Taimet was designed first as an initial screening tool. It surfaces regulatory risk the market may not have priced in - markets, overlaps, vertical exposure, enforcement context - in 10-25 minutes, so your team can test a thesis or identify blind spots before the next call.
But Taimet stops where human judgment begins. Investors still corroborate the market data. Portfolio managers still size the position. The system is built to sharpen expert judgment, not replace it - and every output is designed to be reviewed, challenged, and built upon by the human in the loop.
What Taimet does
- Analyzes broad and narrow market overlaps
- Reasons like an expert antitrust attorney
- Calculates HHI and estimated market shares
- Performs comprehensive vertical analysis
- Assesses state AG and political exposure
- Reviews related actions and prior conduct
- Predicts likely enforcement outcome with a 0-100 score
- Cites sources throughout
What Taimet doesn't do
- Conduct economic modeling (e.g., diversion ratios, merger simulation)
- Accept or process party-supplied documents
- Operate as a chatbot or interactive Q&A tool
- Replace the judgment of expert counsel, analysts, or enforcers
We only need the names of the companies
Taimet doesn't accept uploads. We don't process party-supplied documents. We don't ingest deal materials. To run an analysis, the system needs only the names of the merging companies. This serves three purposes at once:
Security
No party-confidential data ever enters the system, which means none can leak from it.
Anti-gaming
Taimet can't be used as a sandbox to reverse-engineer which factors lower a score. The integrity of the analysis can't be manipulated.
Hallucination is the central problem with using general-purpose LLMs for high-stakes legal and economic analysis. The errors sound plausible. They're hard for a human reviewer to catch. And once a wrong claim enters the pipeline, downstream analysis builds on top of it.
Taimet addresses this with verification passes throughout the analysis. Citation-checking agents confirm that claims are actually supported by the cited sources. Reasoning-consistency checks compare conclusions across agents. Claims without source support are flagged. Different stages of the pipeline cross-validate each other before the report is finalized.
The system checks its own work.
What practitioners are saying
“When you are reviewing multiple transactions with a small team, the constraint isn't judgment, it's time. A tool like this does not replace discretion, but it immediately shows you where to focus it.”
“Reflecting the creator's experience of regulatory matters, the depth of analysis, and more importantly the consistency, is far beyond anything we've seen from general tools. It's genuinely useful for investment decisions.”
“Even as antitrust enforcement becomes less predictable, the need for a clear, consistent view of risk hasn't gone away - if anything, it's more important. Taimet is one of the few tools that brings real structure to that uncertainty. We've been early believers, and it's become a critical part of how we advise investors in live situations.”
“Taimet is the first tool I've seen that genuinely closes the gap between legal analysis and investor needs. It delivers clarity where there used to be noise, and it's quickly become indispensable to how we advise our clients.”
Video WalkthroughSee how Taimet works,
See how Taimet works,
and how easy it is to use.
For investors
Sourced antitrust depth at the pace of a live position.
Everything turns on what regulators will actually do. Taimet gives you that prediction in 10-25 minutes - six real-world outcome bands, with exclusively public data and sources you can check before the trade. Expert-grade antitrust built for the pace of a live position.
10-25 min
Full analysis, not a summary
0-100
Proprietary risk score
~15 hours saved
Per merger analysis
